Target selection for FDA-approved medicines

Michael S. Kinch, Denton Hoyer, Eric Patridge, Mark Plummer

Research output: Contribution to journalShort surveypeer-review

19 Scopus citations

Abstract

The biopharmaceutical industry translates fundamental understanding of disease into new medicines. As part of a comprehensive analysis of FDA-approved new molecular entities (NMEs), we assessed the mechanistic basis of drug efficacy, with emphasis on target selection. Three target families capture almost half of all NMEs and the leading ten families capture more than three-quarters of NME approvals. Target families were related to their clinical application and identify dynamic trends in targeting over time. These data suggest increasing attention toward novel target families, which presumably reflects increased understanding of disease etiology. We also suggest the need to balance the ongoing emphasis on target-based drug discovery with phenotypic approaches to drug discovery.

Original languageEnglish
Article number1532
Pages (from-to)784-789
Number of pages6
JournalDrug Discovery Today
Volume20
Issue number7
DOIs
StatePublished - Jul 9 2015

Fingerprint

Dive into the research topics of 'Target selection for FDA-approved medicines'. Together they form a unique fingerprint.

Cite this